OGT workshop to focus on using latest genomic technologies for accelerating cancer research

OGT workshop provides insight on using complementary genomic technologies

Oxford Gene Technology (OGT), The Molecular Genetics Company, will present a workshop titled ‘An Integrated Genomic Approach to Tumor Profiling’ at the Association for Molecular Pathology (AMP) annual meeting on the 12-15th November at National Harbor, MD.

Research into the identification of clinically relevant genetic mutations is growing rapidly; however, the complexity of genomic variation means that the use of multiple technologies is often required to obtain a complete understanding of a given disease. James Clough, Executive Vice President Commercial, and Ephrem Chin, Business Development Manager at OGT, will explore how next generation sequencing (NGS), microarrays and fluorescence in situ hybridisation (FISH) can be combined to present a fully comprehensive, integrated approach and meet this growing need.

As NGS becomes more affordable, targeted sequencing provides an accurate, high-resolution approach to mutation detection. Developed in collaboration with recognised cancer experts, OGT’s SureSeq™ Solid Tumour Panel covers all exons of key genes for a range of cancer types including breast, prostate, ovarian, lung and colorectal – enabling detection and discovery of both known and novel variants. For detecting copy number variations (CNV), array comparative genomic hybridisation (aCGH) is still the gold standard, and OGT’s CytoSure Cancer +SNP Arrays also provide the facility to uncover LOH information. For certain aberrations such as translocations, however, FISH remains the most reliable mainstream technology, being the final piece of this genomic puzzle explored in OGT’s workshop.

Attendees of the workshop on November 12th, at 2pm in Maryland Ballroom C, will hear how the latest genomic technologies are being applied together to comprehensively characterise genetic abnormalities for accelerating cancer research.

Delegates can also find out more about OGT’s comprehensive molecular genetics solutions at booth 207 and enter a competition for the chance to win a SureSeq™ Solid Tumour Panel, or myProbes™ Custom FISH Probe project.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Oxford Gene Technology. (2019, June 24). OGT workshop to focus on using latest genomic technologies for accelerating cancer research. News-Medical. Retrieved on December 22, 2024 from https://www.news-medical.net/news/20141106/OGT-workshop-to-focus-on-using-latest-genomic-technologies-for-accelerating-cancer-research.aspx.

  • MLA

    Oxford Gene Technology. "OGT workshop to focus on using latest genomic technologies for accelerating cancer research". News-Medical. 22 December 2024. <https://www.news-medical.net/news/20141106/OGT-workshop-to-focus-on-using-latest-genomic-technologies-for-accelerating-cancer-research.aspx>.

  • Chicago

    Oxford Gene Technology. "OGT workshop to focus on using latest genomic technologies for accelerating cancer research". News-Medical. https://www.news-medical.net/news/20141106/OGT-workshop-to-focus-on-using-latest-genomic-technologies-for-accelerating-cancer-research.aspx. (accessed December 22, 2024).

  • Harvard

    Oxford Gene Technology. 2019. OGT workshop to focus on using latest genomic technologies for accelerating cancer research. News-Medical, viewed 22 December 2024, https://www.news-medical.net/news/20141106/OGT-workshop-to-focus-on-using-latest-genomic-technologies-for-accelerating-cancer-research.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
OGT launches high-quality NGS panel for research into Chronic Lymphocytic Leukemia